FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024560361> ?p ?o ?g. }

• W3024560361 endingPage "275" @default.
• W3024560361 startingPage "264" @default.
• W3024560361 abstract "<b><i>Objective:</i></b> Golgi alpha-mannosidase II (GM II) is one of the crucial enzymes in the process of N-glycan processing. The aim of our study was to examine the clinical significance of GM II in patients with clear cell renal cell carcinoma (ccRCC). <b><i>Methods:</i></b> Quantitative reverse transcription polymerase chain reaction analysis and immunohistochemical staining were used to analyze GM II expression in patients with ccRCC. The clinical data of 62 patients with ccRCC were collected to analyze the clinical significance of GM II. The clinical significance among GM II expression, clinicopathological staging, and histological grade of ccRCC was explored. Survival analyses were performed to identify the relevance between the expression of GM II and the overall survival of patients with ccRCC. A uni-/multivariate Cox regression model was used to detect risk factors affecting the prognosis of patients with ccRCC. Subsequently, the proliferation and migration of ccRCC cells were detected after transfecting with GM II-short hairpin RNA (shRNA). <b><i>Results:</i></b> The results of these comparisons suggested that GM II expression of ccRCC tissues was dramatically higher than that of para-carcinoma tissues (<i>p</i> &#x3c; 0.05). GM II expression in the high-differentiation group was lower than that in the median- and low-differentiation groups (<i>p</i> &#x3c; 0.05). GM II expression in stage I and II tissues was lower than that in stage III and IV tissues (<i>p</i> &#x3c; 0.05). The expression levels of GM II in the group without lymph node metastasis were lower than those in the group with lymph node metastasis (<i>p</i> &#x3c; 0.05). Survival analysis indicated that patients with ccRCC with high GM II expression generally had decreased overall survival. Uni-/multivariate Cox model analyses further suggested an association between GM II expression and prognosis of patients with breast cancer. High GM II expression is a potential and independent prognostic biomarker in ccRCC. The inhibition of GM II by transfecting with GM II-shRNA could reduce the proliferation and migration of ccRCC. <b><i>Conclusion:</i></b> GM II expression in human ccRCC tissues was upregulated compared with that found in normal human renal tissue, and GM II may promote the progression and migration of ccRCC. Furthermore, the GM II gene may be used as a promising tumor marker for the diagnosis and prognosis of ccRCC." @default.
• W3024560361 created "2020-05-21" @default.
• W3024560361 creator A5003322678 @default.
• W3024560361 creator A5023713376 @default.
• W3024560361 creator A5041491935 @default.
• W3024560361 creator A5050590989 @default.
• W3024560361 creator A5063825630 @default.
• W3024560361 creator A5065833423 @default.
• W3024560361 date "2020-01-01" @default.
• W3024560361 modified "2023-10-01" @default.
• W3024560361 title "Golgi Alpha-Mannosidase II as a Novel Biomarker Predicts Prognosis in Clear Cell Renal Cell Carcinoma" @default.
• W3024560361 cites W1182461782 @default.
• W3024560361 cites W1967080411 @default.
• W3024560361 cites W1976022047 @default.
• W3024560361 cites W1976043651 @default.
• W3024560361 cites W1984026274 @default.
• W3024560361 cites W1987977871 @default.
• W3024560361 cites W1991019518 @default.
• W3024560361 cites W2000342638 @default.
• W3024560361 cites W2017887262 @default.
• W3024560361 cites W2021592757 @default.
• W3024560361 cites W2035138836 @default.
• W3024560361 cites W2045082439 @default.
• W3024560361 cites W2052039807 @default.
• W3024560361 cites W2059529313 @default.
• W3024560361 cites W2066604995 @default.
• W3024560361 cites W2079592207 @default.
• W3024560361 cites W2080477888 @default.
• W3024560361 cites W2091081051 @default.
• W3024560361 cites W2094614586 @default.
• W3024560361 cites W2099343588 @default.
• W3024560361 cites W2107277218 @default.
• W3024560361 cites W2109202643 @default.
• W3024560361 cites W2128687047 @default.
• W3024560361 cites W2131027577 @default.
• W3024560361 cites W2131595192 @default.
• W3024560361 cites W2134294354 @default.
• W3024560361 cites W2137462525 @default.
• W3024560361 cites W2164203665 @default.
• W3024560361 cites W2235523093 @default.
• W3024560361 cites W2293962048 @default.
• W3024560361 cites W2564893946 @default.
• W3024560361 cites W2622954435 @default.
• W3024560361 cites W2791482956 @default.
• W3024560361 cites W2793169963 @default.
• W3024560361 cites W2885706430 @default.
• W3024560361 cites W2889587890 @default.
• W3024560361 cites W2902620090 @default.
• W3024560361 cites W2930148820 @default.
• W3024560361 cites W2948386661 @default.
• W3024560361 cites W2948823748 @default.
• W3024560361 cites W2988624750 @default.
• W3024560361 doi "https://doi.org/10.1159/000505931" @default.
• W3024560361 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32403105" @default.
• W3024560361 hasPublicationYear "2020" @default.
• W3024560361 type Work @default.
• W3024560361 sameAs 3024560361 @default.
• W3024560361 citedByCount "3" @default.
• W3024560361 countsByYear W30245603612022 @default.
• W3024560361 countsByYear W30245603612023 @default.
• W3024560361 crossrefType "journal-article" @default.
• W3024560361 hasAuthorship W3024560361A5003322678 @default.
• W3024560361 hasAuthorship W3024560361A5023713376 @default.
• W3024560361 hasAuthorship W3024560361A5041491935 @default.
• W3024560361 hasAuthorship W3024560361A5050590989 @default.
• W3024560361 hasAuthorship W3024560361A5063825630 @default.
• W3024560361 hasAuthorship W3024560361A5065833423 @default.
• W3024560361 hasConcept C126322002 @default.
• W3024560361 hasConcept C173396325 @default.
• W3024560361 hasConcept C190232843 @default.
• W3024560361 hasConcept C190283241 @default.
• W3024560361 hasConcept C204232928 @default.
• W3024560361 hasConcept C2777472916 @default.
• W3024560361 hasConcept C2778560582 @default.
• W3024560361 hasConcept C2781197716 @default.
• W3024560361 hasConcept C2781278892 @default.
• W3024560361 hasConcept C502942594 @default.
• W3024560361 hasConcept C55493867 @default.
• W3024560361 hasConcept C63363279 @default.
• W3024560361 hasConcept C71924100 @default.
• W3024560361 hasConcept C86803240 @default.
• W3024560361 hasConceptScore W3024560361C126322002 @default.
• W3024560361 hasConceptScore W3024560361C173396325 @default.
• W3024560361 hasConceptScore W3024560361C190232843 @default.
• W3024560361 hasConceptScore W3024560361C190283241 @default.
• W3024560361 hasConceptScore W3024560361C204232928 @default.
• W3024560361 hasConceptScore W3024560361C2777472916 @default.
• W3024560361 hasConceptScore W3024560361C2778560582 @default.
• W3024560361 hasConceptScore W3024560361C2781197716 @default.
• W3024560361 hasConceptScore W3024560361C2781278892 @default.
• W3024560361 hasConceptScore W3024560361C502942594 @default.
• W3024560361 hasConceptScore W3024560361C55493867 @default.
• W3024560361 hasConceptScore W3024560361C63363279 @default.
• W3024560361 hasConceptScore W3024560361C71924100 @default.
• W3024560361 hasConceptScore W3024560361C86803240 @default.
• W3024560361 hasIssue "6" @default.
• W3024560361 hasLocation W30245603611 @default.
• W3024560361 hasLocation W30245603612 @default.

• next